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Abstract
Background: Yeasts, mostly Candida, are important causes of bloodstream infections (BSI), responsible for significant
mortality and morbidity among hospitalized patients. The epidemiology and species distribution vary from different
regions. The goals of this study were to report the current epidemiology of Candida BSI in a Shanghai Teaching
Hospital and estimate the impact of appropriate antifungal therapy on the outcome.
Methods: From January 2008 to December 2012, all consecutive patients who developed Candida BSI at Ruijin
University Hospital were enrolled. Underlying diseases, clinical severity, species distribution, antifungal therapy and its
impact on the outcome were analyzed.
Results: A total of 121 episodes of Candida BSI were identified, with an incidence of 0.32 episodes/1,000 admissions
(0.21 in 2008 and 0.42 in 2012) The proportion of candidemia caused by non-albicans species (62.8%), including
C. parapsilosis (19.8%), C. tropicalis (14.9%), C. glabrata (7.4%), C. guilliermondii (5.8%), C. sake (5.0%) was higher
than that of candidemia caused by C. albicans (37.2%). The overall crude 28-day mortality was 28.1% and significantly
reduced with appropriate empiric antifungal therapy administered within 5 days (P = 0.006). Advanced age (OR 1.04;
P = 0.014), neutropenia < 500/mm3 (OR 17.44; P < 0.001) were independent risk factors for 28-day mortality, while
appropriate empiric antifungal therapy (OR 0.369; P = 0.035) was protective against 28-day mortality.
Conclusion: The epidemiology of candidemia in Shanghai differed from that observed in Western countries.
Appropriate empiric antifungal therapy influenced the short-term survival.
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Background
Yeasts, mostly Candida spp. are currently between the
fourth and the sixth most common nosocomial blood-
stream isolate in American and European studies [1,2].
However, their incidences vary according to geography
but overall continue to increase worldwide [3-6] except
in North America and China [4,7,8]. Risk factors include
exposure to broad-spectrum antibacterial agents, increased
complexity of surgical procedures, prolonged use of central
venous catheters, dialysis, corticosteroids and cytotoxic
chemotherapy [9].
Although C. albicans has long been the most common
species isolated during candidemia, recent studies have
demonstrated a shift towards non-albicans species, such as
C. parapsilosis, C. glabrata and C. krusei [3,10], especially
in intensive care unit and hematological patients [11-13]
and/or in case of antifungal pre-exposure [14,15]. Guide-
lines on the treatment of candidemia have been developed
[16,17], with a consensus that all candidemic patients
should receive antifungal therapy. Although novel anti-
fungal drugs have been developed since the last decade,
90-day mortality rates due to candidemia remain as high
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as 50-70% [12,18,19]. In addition, data from several
studies showed that 30-day mortality rates and costs of
care increased significantly when empirical therapy was
delayed or inadequate (inappropriate dosage, resistant
isolate) [20-24].
We provide herein a laboratory-based report from a
tertiary care hospital in Shanghai, China, assessing the
epidemiology, species distribution, antifungal therapy
and outcome of Candida blood stream infection (BSI).
Risk factors related to 28-day crude mortality were also
analyzed.
Methods
A retrospective analysis of consecutive Candida blood-
stream episodes in adults collected from the microbiology
database of a 1300-bed tertiary care hospital in Shanghai,
China was performed over a 5-year period.
Demographics, underlying diseases, co-morbidities, se-
verity of clinical features, Candida species distribution,
time from admission to onset and turnaround time (TAT)
of final report of blood culture were compared among the
patients infected with different Candida species.
A case of Candida BSI was defined as a patient with
at least one blood culture positive for a Candida.
Definition of sepsis was signs and symptoms of in-
flammation plus infection with hyper- or hypothermia
(core temperature >38.3°C or <36.0°C), tachycardia
(90 min−1 or more than two SD above the normal value
for age), and at least one following tachypnea or
leukocytosis (WBC count > 12,000/mm3) or leucopenia
(WBC count <4,000/mm3) or normal WBC count with
greater than 10% immature forms.
\Neutropenia was defined as <500/mm3 absolute
neutrophil count. Prior corticosteroid was defined as
receiving >1 mg/kg/d prednisone for more than 1 week
or equivalent before Candida BSI onset.
Isolates were detected from blood cultures using the
BACTEC™ FX system (Becton Dickinson, Inc., Sparks,
MD, USA). Flucytosine, amphotericin B, fluconazole, vori-
conazole, and itraconazole susceptibility testings were per-
formed using the ATB® FUNGUS 3 system (BioMérieux,
France), which was wildly used in China [25], providing
susceptibility to antifungals results markedly concordant
with those obtained using CLSI and EUCAST method-
ologies [26]. For triazoles, the minimal inhibitory con-
centration (MIC) was determined by determining the
concentration at which a prominent reduction in the
yeast cell count was observed after 24 h of treatment.
The MIC for amphotericin B and flucytosine were de-
fined as the lowest concentration at which no visible
growth was detected. CLSI-24 h resistance breakpoints
(CBPs) [27] for fluconazole, itraconazole and voriconazole,
recently approved, were used: susceptible (S) ≤2 μg/mL,
susceptible dose-dependent (SDD) 4 μg/mL, and resistant
(R) ≥8 μg/mL for fluconazole and C. albicans, C. tropica-
lis, and C. parapsilosis and ≤32 μg/mL (SDD), ≥64 μg/mL
(R) for C. glabrata; S ≤0.12 μg/mL, SDD 0.25-0.5 μg/mL,
R ≥1 μg/mL for voriconazole and C. albicans, C. tropicalis,
and C. parapsilosis, and ≤ 0.5 μg/mL (S), 1 μg/mL
(SDD), ≥2 μg/mL (R) for C. krusei; S ≤ 0.12 μg/m, SDD
0.25-0.5 μg/mL, R ≥1 μg/mL for itraconazole and C.
albicans. Due to lack of CBPs of amphotericin B and
flucytosine for Candida spp. and itraconazole for Candida
non-albicans, the epidemiological cutoff values (ECVs)
[27] were used for them: S ≤2ug/mL, R > 2ug/mL for
amphotericin B and Candida spp.; S ≤0.5ug/mL, R >
0.5ug/mL for flucytosine and C. albicans, C. tropicalis, C.
glabrata and C. parapsilosis; S ≤32 ug/mL, R > 32ug/mL
for flucytosine and C. krusei, S ≤1ug/mL, R > 1ug/mL for
flucytosine and C. guilliermondii; S ≤0.5ug/mL, R > 0.5ug/mL
for itraconazole and C. parapsilosis and C. tropicalis;
S ≤1ug/mL, R > 1ug/mL for itraconazole and C. krusei and
C. guilliermondii; S ≤2ug/mL, R > 2ug/mL for itraconazole
and C. glabrata.
Initial appropriate antifungal treatment was considered
when the appropriate drug (based on subsequent in vitro
susceptibility results) with adequate dosage was started
within 5 days the first blood culture performed. Adequate
dosage of antifungal agent was defined according to
IDSA 2009 guidelines [16]: 400-600 mg/d fluconazole for
fluconazole susceptible Candida spp.; ≥0.5 mg/kg/d of
amphotericin B deoxycholate; ≥3 mg/kg/d of any lipid
formulation of amphotericin B; 70 mg of caspofungin × 1
dose followed by 50 mg/d and 6 mg/kg of voriconazole b.
i.d. × 2 doses followed by ≥ 3 mg/kg b.i.d.. Patients who
did not receive any antifungal were considered as having
received inappropriate therapy.
Crude mortality was registered after 28 days from the
occurrence of the episode of Candida BSI.
The study was approved by the local institutional review
board (Ruijin Hospital, Shanghai Jiaotong University,
School of medicine) and written patient consent was not
required because of the observational nature of this study.
Statistics analysis
Descriptive analyses were used for baseline characteristics
and subgroup analyses (by Candida species). Continuous
variables such as age, length of hospital stay, time from
admission to infection and TAT of final results of blood
culture were expressed either as means and standard
deviations (SD). The Chi-square-test or 2-tailed Fisher
Exact-test was used to compare categorical variables.
The survival distribution function was estimated using
the Kaplan-Meier method. To define risk factors for
mortality, multivariate logistic regression analysis and
adjusted odds ratio (OR) with 95% confidence interval
(CI) were calculated. Variables that were associated with
28-day mortality in univariate analyses with a P value
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of < 0.16 were entered into multivariate analysis. 2-tailed tests
of significance at the level of a P value of <0.05 level were
used to determine statistical significance. Statistical analysis
has been conducted by using the program SPSS 19.0.
Results
Incidence and demographic characteristics of patients
A total of 121 episodes of yeast BSI were identified dur-
ing the study period (1st January 2008 to 31st December
2012), with an incidence of 0.32 episodes/1000 admis-
sions. The incidence increased from 0.21 in 2008 to 0.42
episodes/1000 admissions in 2012 (0.21 in 2008, 0.24 in
2009, 0.26 in 2010, 0.44 in 2011 and 0.42 in 2012). The
number of blood culture/1000 admissions obtained
yearly in our hospital was 118.2, 116.0, 117.9, 147.6 and
166.1, respectively, while in ICUs, the number of blood
culture/all blood culture yearly was 11.4%, 11.7%, 11.3%,
11.1% and 12.3%, respectively. All cases were nosocomi-
ally acquired.
The demographic characteristics of the patients are
summarized in Table 1. The mean age of patients was
57.3 years and 71.9% were male. The distribution of C.
albicans and non-albicans strains had no significant dif-
ference according to patients’ origin (p = 0.07), as shown
in Figure 1. C. albicans was isolated in 18.5% of cases in
internal medical wards while in 43.5% and 41.7% in ICU
and surgery wards, respectively. However, there were a
higher proportion of C. parapsilosis and C. tropicalis iso-
lates in internal medical ward than in ICU or surgery
ward. Mean TAT for C. glabrata (6.11 ± 1.36 d) was sig-
nificantly higher than that observed for other Candida
species (3.9-4.8 ± 0.8-1.5 d) (P = 0.002).
Underlying diseases and clinical features
The majority of patients (95.0%) had at least one co-
morbidity at the time of the diagnosis of Candida BSI.
Twenty-six patients (21.5%) had solid organ tumor, 18
(14.9%) had hematologic malignancy, 16 (13.2%) had dia-
betes mellitus, 12 (9.9%) had chronic renal failure, 32
(26.4%) had cardiac disease and 26 (21.5%) had chronic
pulmonary disease. Twenty patients (16.5%) received cor-
ticosteroids, 66 (54.5%) underwent a surgical intervention
within 30 days and 16 (13.2%) had received antifungal
agents as prophylaxis or empirical therapy within 30 days
prior to their onset of Candida BSI. Sixty-eight (56.2%)
patients had at least two co-morbidities. No patient had
human immunodeficiency virus (HIV) infection. Regard-
ing the severity of clinical feature, 48 (39.7%) received at
least 7-day parenteral nutrition, 22 (18.2%) were mechan-
ically ventilated, 12 (9.9%) had renal replacement therapy,
and 14 (11.6%) had absolute neutrophil count < 500/mm3.
Patients infected with C. parapsilosis, C. glabrata or C.
krusei had lower rate (44%-60%) of sepsis signs compared
to those infected with other Candida spp. (more than
85%). The clinical characteristics (underlying disease,
severity of clinical feature) of the patients, by Candida
species are shown in Table 2.
Candida species and antifungal susceptibility testing
Forty-five (37.2%) of Candida BSI were C. albicans and 76
(62.8%) were non-albicans Candida. In non-albicans Can-
dida sepsis cases, 24 (19.8%) were caused by C. parapsilosis,
18 (14.9%) by C. tropicalis, 9 (7.4%) by C. glabrata, 7 (5.8%)
by C. guilliermondii, 6 (5.0%) by C. sake, 5 (4.1%) by C.
krusei, 2 (1.7%) by C. lusitaniae, 2 (1.7%) by C. intermedia,
2 (1.7%) by C. theae and 1 (0.8%) by C. haemulonii.
Based on CLSI breakpoints 2012 (CBPs) [27], the rate of
susceptibility to fluconazole was 93.0%, 95.8%, 66.7%,
85.7%, 100% and 0% for C. albicans, C. parapsilosis, C. tro-
picalis, C. guilliermondii, C. sake and C. krusei, respect-
ively. The rate of susceptibility to itraconazole was lower
in C. albicans in our study (79.1%) when compared to flu-
conazole (93.0%) and voriconazole (95.3%). Amphotericin
B and 5-flucytosine remained close to 100% susceptibility
against common Candida spp., except for C. krusei
and C. guilliermondii (only 20% and 71.4% susceptible
to flucytosine, respectively), according to ECVs [27]
(showed in Table 3).
Antifungal therapy and outcome
Empiric antifungal therapy was administered in 97
(80.2%) of the cases while 24 (19.8%) patients did not
receive any antifungal treatment. Fluconazole was most
frequently used (62.9%), followed by caspofungin (18.5%)
and any formulation of amphotericin B for (6.2%). Four
patients (4.1%) received a combination therapy (flucona-
zole + caspofungin and fluconazole + amphotericin B in
2 cases each). Eighty-six (71.1%) of 121 patients with
Candida BSI received an appropriate empiric antifungal
agent.
Patient outcomes at 28-day, stratified by yeast species,
are reported in Table 2. The overall, 28-day crude mortal-
ity rate was 28.1%. Mortality rate was significantly higher
in internal medicine than in surgical wards or in ICU
(48.1% vs. 17.4% or 27.1%, respectively, p = 0.018). Though
still considerable, mortality was significantly lower for
those who received appropriate empiric antifungal therapy
than inappropriate empiric antifungal therapy (20.9% vs.
45.7%, p = 0.006) within 5 days the first positive blood cul-
ture performed (shown in Figure 2). There was a signifi-
cant difference in survival between the two groups [Log
Rank (mantel-Cox) chi-square =12.784, P < 0.001] (shown
in Figure 3).
In univariate analysis, gender (male), presence of sepsis,
neutropenia and appropriate empiric antifungal therapy
were associated with 28-day mortality. In multivariate
analysis, advanced age (OR, 1.038; 95% CI, 1.007-1.069;
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Age (years, Mean±SD) 61.7±16.7 62.5±19.7 46.8±21.1 56.1±24.1 58.6±10.6 54.3±18.9 40.8±27.1 52.6±24.4 57.3±19.9 0.07
Male sex, n(%) 32(71.7) 17(70.8) 14(77.8) 9 (100) 3 (42.9) 6 (100) 2 (40.0) 4 (57.1) 87 (71.9) -
Orginal n(%)
Internal Medicine ward 5(11.2) 8(33.3) 7 (38.9) 1 (11.2) 0 (0) 0 (0) 3 (60.0) 3 (42.9) 27 (22.3) -
Surgery ward 20(44.4) 7(29.2) 5(27.8) 4 (44.4) 5 (71.4) 4 (66.7) 0 (0) 1 (14.3) 46 (38.0) -
Intensive care unit 20(44.4) 9(37.5) 6 (33.3) 4 (44.4) 2 (28.6) 2 (33.3) 2 (40.0) 3 (42.9) 48 (39.7) -
Time from admission to
infection
29.5±37.6 35.9±32.3 31.8±26.1 38.7±23.4 31.4±21.3
152.8
±278.3
64.2±68.6 26.9±17.2 39.3±70.7 0.01
(day, Mean±SD)
Length of hospitalization 62.1±68.6 66.0±45.4 61.1±48.8 85.0±57.4 50.7±29.7
224.3
±317.8
92.4±88.5 87.9±145.7 74.6±97.7 0.02
(day, Mean±SD)
Turnaround time (TAT) 4.04±1.36 4.83±0.82 3.94±1.43 6.11±1.36 4.43±1.13 4.33±1.75 4.40±1.52 4.86±1.22 4.44±1.38 0.002
(day, Mean±SD)



















P = 0.014), neutropenia (OR, 17.442; 95% CI 3.555-
85.582; P < 0.001) and appropriate empiric antifungal
therapy (OR, 0.369; 95% CI 0.146-0.934; P = 0.035)
remained independent risk factors for 28-day mortality
(Table 4).
Discussion
Our data show that in our teaching hospital in Shanghai,
the incidence of candidemia has increased steadily in the
past 5 years (0.21 to 0.42 episodes per 1,000 admissions).
Several studies have shown a substantial increase in the





















Solid tumor 14 (31.1) 4 (16.7) 2 (11.1) 2 (22.2) 3 (42.9) 1 (16.7) 0 (0) 0 (0) 26 (21.5)
Hematologic malignancy 3 (6.7) 2 (8.3) 6 (33.3) 1 (11.1) 0 (0) 1 (16.7) 3 (60.0) 2 (28.6) 18 (14.9)
Diabetes mellitus 5 (11.1) 5 (20.8) 1 (5.6) 3 (33.3) 0 (0) 1 (16.7) 0 (0) 1 (14.3) 16 (13.2)
Cardiac disease 13 (28.9) 5 (20.8) 3 (16.7) 4 (44.4) 2 (28.6) 2 (33.3) 2 (40.0) 1 (14.3) 32 (26.4)
Chronic pulmonary
disease
13 (28.9) 4 (16.7) 2 (11.1) 2 (22.2) 1 (14.3) 1 (16.7) 1 (20.0) 2 (28.6) 26 (21.5)
Prior surgical intervention
(<30 days)
28 (62.2) 10 (41.7) 9 (50.0) 5 (55.6) 6 (85.7) 4 (66.7) 2 (40.0) 2 (28.6) 66 (54.5)
Corticosteroid use 7 (15.6) 4 (16.7) 2 (11.1) 2 (22.2) 0 (0) 0 (0) 3 (60.0) 2 (28.6) 20 (16.5)
Prior antifungal agents
use (<30 days)
1 (2.2) 5 (20.8) 2 (11.1) 2 (22.2) 1 (14.3) 1 (16.7) 4 (80.0) 0 (0) 16 (13.2)
Severity of clinical feature
Parenteral nutrition 20 (44.4) 9 (37.5) 3 (16.7) 7 (77.8) 3 (42.9) 2 (33.3) 2 (40.0) 2 (28.6) 48 (39.7)
Mechanical ventilation 9 (20.0) 4 (16.7) 1 (5.6) 5 (55.6) 0 (0) 1 (16.7) 2 (40.0) 0 (0) 22 (18.2)
Sepsis 40 (88.9) 14 (58.3) 17 (94.4) 4 (44.4) 6 (85.7) 5 (83.3) 3 (60.0) 6 (85.7) 95 (78.5)
Renal replacement
therapy
6 (13.3) 2 (8.3) 0 (0) 2 (22.2) 1 (14.3) 0 (0) 1 (20.0) 0 (0) 12 (9.9)
Central venous catheter 37 (82.2) 16 (66.7) 13 (72.2) 9 (100) 6 (85.7) 4 (66.7) 4 (80.0) 6 (85.7) 95 (78.5)
Neutropenia 2 (4.4) 0 (0) 6 (33.3) 1 (11.1) 0 (0) 0 (0) 3 (60.0) 2 (28.6) 14 (11.6)
28-day mortality 16 (35.6) 4 (16.7) 7 (38.9) 0 (0) 1 (14.3) 0 (0) 2 (40.0) 4 (57.1) 34 (28.1)
*Other Candida spp. includes C. lusitaniae (2), C. intermedia (2), C. theae (2) and C. haemulonii (1).
Figure 1 Distribution of the Candida species by origin [C. albicans vs. C. non-albicans (p = 0.074)].
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incidence of candidemia in the past 2 decades [3-5], with
an incidence of 0.3-1.0 episodes per 1000 admissions
elsewhere in China [28], North America [29,30] and some
European countries [3,31,32], much higher (1.2 to 1.7 epi-
sodes) in Latin America [33] and Italy [3], and much lower
in Northern Europe (0.01 to 0.08 episodes) [34,35].
Species distribution here consisted in C. albicans,
followed by C. parapsilosis, C. tropicalis and C. glabrata,
overall accounting for more than 70% of episodes of can-
didemia. Although C. albicans is still considered the most
common species causing candidemia, trends of increasing
rates of non-C. albicans have been reported worldwide
Figure 2 Relationship between hospital mortality (28-day) and the timing of antifungal treatment. The timing of antifungal therapy was
determined to be from the time when the first blood sample for culture that was positive for fungi was drawn to the time when appropriate
antifungal treatment was first administered to the patient. 28-day mortality was significantly lower for those who received appropriate empiric
antifungal therapy within 120 h (5d) vs. inappropriate or delayed (>5d) empiric antifungal therapy or no antifungal treatment (20.9% vs.
45.7%, p = 0.006).
Table 3 Antifungal susceptibility testing results (ATB Fungus 3) of 105 Candida isolates in Shanghai according to new
species-specific clinical breakpoints (CBPs) or epidemiologic cutoff values (ECVs) defined by the CLSI [27]
C. albicans (n=43) C. parapsilosis (n=24) C. tropicalis (n=18) C. glabrata (n=8) C. guilliermondii (n=7) C. krusei (n=5)
Fluconazole
Susceptible 40 (93.0) 23 (95.8) 12 (66.7) 0 (0) 6 (85.7) 0 (0)
SDD 0 (0) 0 (0) 1 (5.5) 8 (100) 0 (0) 0 (0)
Resistance 3 (7.0) 1 (4.2) 5 (27.8) 0 (0) 1 (14.3) 5 (100)
Itraconazole
Susceptible 34 (79.1) 23 (95.8) 11 (61.1) 4 (50.0) 5 (71.4) 1 (20.0)
SDD 5 (11.6) - - - - -
Resistance 4 (9.3) 1 (4.2) 7 (38.9) 4 (50.0) 2 (28.6) 4 (80.0)
Voriconazole
Susceptible 41 (95.3) 23 (95.8) 13 (72.2) 8 (100) 5 (71.4) 4 (80.0)
SDD 0 (0) 0 (0) 1 (5.6) 0 (0) 0 (0) 0 (0)
Resistance 2 (4.7) 1 (4.2) 4 (22.2) 0 (0) 2 (28.6) 1 (20.0)
Amphotericin B
Susceptible 43 (100) 24 (100) 18 (100) 8 (100) 6 (85.7) 5 (100)
Resistance 0 (0) 0 (0) 0 (0) 0 (0) 1 (14.3) 0 (0)
Flucytosine
Susceptible 42 (97.7) 24 (100) 18 (100) 8 (100) 5 (71.4) 1 (20.0)
Resistance 1 (2.3) 0 (0) 0 (0) 0 (0) 2 (28.6) 4 (80.0)
SDD: susceptible dose dependence.
Due to lack of CBPs of amphotericin B and flucytosine for Candida spp. and itraconazole for Candida non-albicans, the epidemiological cutoff values (ECVs) were
used [27].
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Table 4 Risk factors for 28-day mortality of candidemia in Shanghai (n=121 episodes)
28-day outcome Mutlivariate analysis
Survival (n=87) Death (n=34) P value OR (95% CI) P value
Gender, male [n(%)] 67 (77.0) 20 (58.8) 0.045 - 0.25
Age (years, Mean±SD) 55.70±20.71 61.38±17.29 0.159 1.038 (1.007-1.069) 0.014
Underlying disease
Solid tumor [n(%)] 15 (17.2) 11 (32.4) 0.069 - 0.177
Hematologic malignancy [n(%)] 10 (11.5) 8 (23.5) 0.094 - 0.313
Diabetes mellitus [n(%)] 10 (11.5) 6 (17.6) 0.369 - -
Cardiac disease [n(%)] 26 (29.9) 6 (17.60 0.17 - -
Pulmonary disease [n(%)] 17 (19.5) 9 (26.5) 0.404 - -
Prior surgical intervention (<30 days) [n(%)] 51 (58.6) 15 (44.1) 0.15 - 0.806
Prior antifungal agents use (<30 days) [n(%)] 13 (14.9) 3 (8.8) 0.372 - -
Corticosteroid use [n(%)] 13 (14.9) 7 (20.6) 0.452 - -
Severity of clinical feature
Sepsis [n(%)] 64 (73.6) 31 (91.2) 0.034 - 0.087
Renal replacement therapy [n(%)] 7 (8.0) 5 (14.7) 0.445 - -
Parenteral nutrition [n(%)] 34 (39.1) 14 (41.2) 0.832 - -
Mechanical ventilation [n(%)] 15 (17.2) 7 (20.6) 0.668 - -
Central venous catheter [n(%)] 68 (78.2) 27 (79.4) 0.88 - -
Neutropenia [n(%)] 5 (5.7) 9 (26.5) 0.004 17.442 (3.555-85.582) <0.001
Antifungal therapy within 5 days the first blood culture performed
Appropriate empiric therapy 68 (78.2) 18 (52.9)
0.006 0.369 (0.146-0.934) 0.035
Inappropriate empiric therapy 19 (21.8) 16 (47.1)
Figure 3 Kaplan–Meier survival curves (28-day) based on the initiation of empiric appropriate antifungal therapy [Log Rank (mantel-Cox)
chi-square =12.784, p < 0.001].
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[3,10,36], which was also observed in our study (37.2% for
C. albicans vs. 62.8% for non-C. albicans). The reasons for
the emergence of non-C. albicans species are not fully
understood, but some studies recently showed that
medical conditions may influence the risk of developing
non-C. albicans invasive infection. Indeed, C. parapsilosis
candidemia has been associated with vascular catheters,
parenteral nutrition and prior exposure to echinocandins
[11]. C. tropicalis is associated with older age, cancer and
neutropenia [37,38], and C. krusei and C. glabrata are
associated with previous exposure to azoles and echino-
candins [39,40]. Although no statistical analysis was
performed here on the interaction between patient’s
clinical features and Candida species, because of small
sample size, the trends of distribution are partially sup-
portive of these reports: 33-60% patients infected with
C. tropicalis or C. krusei had hematologic malignancy
and neutropenia; four of five (80%) patients infected
with C. krusei had prior use of antifungal therapy; 40-55%
patients infected with C. glabrata or C. krusei received
mechanical ventilation. Of note, our study showed that
presence of sepsis symptoms was predominant in patients
infected with C. albicans (88.9%), C. tropicalis (94.4%), C.
guilliermondii (85.7%) and C. sake (83.3%) rather than in
patients infected by other Candida species (44.4%-60.0%).
Interestingly, we observed in the present study that C.
guilliermondii and C. sake represented 5.8% and 5.0% of
the isolates; while only 0.2%-2.4% of C. guilliermondii
was observed in European countries [11,18,41,42], in
Taiwan [43] and in Latin America except in Honduras
(20%) [33]. The emergence of severe sepsis due to C. sake
is here remarkable, knowing that the latter species repre-
sented only 0.03% of isolates in a recent publication from
ARTEMIS [44].
A lower percentage of C. albicans (18.5%) was observed
in internal medicine wards compared with surgical wards
(43.5%) and ICU (41.7%) while C. tropicalis and C. para-
psilosis were more frequent in internal medicine wards.
Antifungal resistance was a rare finding in our study
and was restricted to azoles, except in C. tropicalis.
We found a higher rate of fluconazole SDD or resist-
ance C. tropicalis here (5.5% and 27.8%, respectively),
while other studies showed a prevalence of less than
10% [4,33,45-47].
In the present study, almost 19.8% of patients did not
receive any antifungal treatment. The most likely reasons
were late diagnosis, since one-third of these patients died
within 7 days after the onset candidemia, and the poor
compliance to antifungal therapy in some wards. Flucona-
zole was the most frequently administered antifungal
agents as empiric therapy, followed by the echinocandins.
Echinocandins were used infrequently despite their effi-
cacy in the treatment of candidemia and their recom-
mendation to be used as first line therapy in the recent
ESCMID guidelines [17,48], because of their price com-
pared with fluconazole.
We report an overall, 28-day crude mortality rate of
28.1%. A statistically significant finding is the high 28-day
mortality rate for Candida BSI in patients from internal
medicine wards compared with other wards. The factors
contributing towards poor short-term survival in internal
medicine should be explored in future studies.
Another major finding in the present study was that
delay in initial appropriate empirical treatment for Can-
dida BSI of at least 5 days after the first blood culture was
performed was associated with a greater risk of 28-day
mortality. Our results confirm recent studies’ results, in
which a relationship between delaying the initiation of an-
tifungal therapy and mortality was demonstrated [24,49].
For example, Bassetti et al. [49] showed that the initiation
of antifungal treatment 48 h after having the first positive
blood culture report was an independent determinant of
hospital mortality. The results of previous studies on this
topic have yielded conflicting results [20,21,50]. Hsu et al.
[50] investigated patients who received an echinocandin
for Candida BSI; early (<3 days) versus late (>3 days) initi-
ation of caspofungin was not associated with hospital
mortality. Parkins et al. [20] showed although appropriate
empirical antifungal therapy was protective against
hospital mortality, no association was found between
timing of antifungal administration and mortality. Simi-
larly, Kludze-Forson et al. [21] reported the lack of any
association between the timing of appropriate antifungal
therapy and hospital mortality; of note, increased APA-
CHE II score was the only independent predictor of
mortality.
Reasons for observing different results among various
studies investigating the impact of timing of antifungal
therapy on outcomes is unknown, but multiple complex
factors are likely responsible. Our study showed in
multivariate logistic regression analysis, the significant
association between 3 variables (age, neutropenia and
appropriate empiric antifungal therapy) and 28-day mor-
tality. Appropriate empiric antifungal therapy was here a
protective factor.
Although providing data from a large university hospital
in Shanghai, our study has some important limitations,
the most significant being its retrospective nature. The
severity of illness score (such as APACHE II score), timing
of CVC removal were not included because of missing
data. Second, our study was monocentric and the results
may not be applicable to other settings.
Conclusions
In conclusion, our retrospective study showed the inci-
dence of candidemia has increased in the past 5 years in
Shanghai. We observed a predominance of non-C. albi-
cans Candida species, with C. guilliermondii and C. sake
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representing more than 10% of the isolates. However C.
albicans remained the most frequently isolated species.
28-day mortality in internal medicine wards was un-
acceptably high. Finally, appropriate empiric antifungal
therapy influenced the short-term survival of patients
with candidemia.
Key messages
The incidence of candidemia has increased in the past
5 years at Ruijin hospital in Shanghai.
C. albicans remained the most frequently isolated species,
while a predominance of non-C. albicans Candida species
was observed, with C. guilliermondii and C. sake represent-
ing more than 10% of the isolates.
Twenty-eight-day mortality rate was significantly higher
in internal medicine than in surgical wards or in ICU.
Advanced age, neutropenia and appropriate empiric
antifungal therapy remained independent risk factors for
28-day mortality.
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